Alphatec (ATEC) versus FRESENIUS SE &/S (FSNUY) Head-To-Head Survey

Alphatec (NASDAQ: ATEC) and FRESENIUS SE &/S (OTCMKTS:FSNUY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings.

Volatility & Risk

Alphatec has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, FRESENIUS SE &/S has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

Profitability

This table compares Alphatec and FRESENIUS SE &/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alphatec 1.37% N/A -1.86%
FRESENIUS SE &/S 5.35% 8.43% 3.39%

Institutional and Insider Ownership

18.0% of Alphatec shares are held by institutional investors. Comparatively, 0.1% of FRESENIUS SE &/S shares are held by institutional investors. 44.4% of Alphatec shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Alphatec and FRESENIUS SE &/S’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alphatec $101.74 million 0.74 -$2.29 million ($0.36) -8.19
FRESENIUS SE &/S $38.28 billion 1.18 $2.05 billion N/A N/A

FRESENIUS SE &/S has higher revenue and earnings than Alphatec.

Dividends

FRESENIUS SE &/S pays an annual dividend of $0.15 per share and has a dividend yield of 0.7%. Alphatec does not pay a dividend.

Analyst Ratings

This is a summary of current recommendations and price targets for Alphatec and FRESENIUS SE &/S, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alphatec 0 0 2 0 3.00
FRESENIUS SE &/S 1 0 0 0 1.00

Alphatec presently has a consensus target price of $5.50, suggesting a potential upside of 86.44%. Given Alphatec’s stronger consensus rating and higher probable upside, research analysts clearly believe Alphatec is more favorable than FRESENIUS SE &/S.

Summary

FRESENIUS SE &/S beats Alphatec on 9 of the 14 factors compared between the two stocks.

Alphatec Company Profile

Alphatec Holdings, Inc., a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures. The company offers MIS products consisting of Battalion Lateral Spacer System and Squadron Lateral Retractor, Illico Minimally Invasive Surgery System, and BridgePoint Spinous Process Fixation System; and fixation products, such as Arsenal Screw System and Zodiac Spinal Fixation Systems. It also provides cervical and cervico-thoracic products, including Trestle Luxe Anterior Cervical Plate System, and Solanas Posterior Cervico/Thoracic Fixation System and Avalon Occipital Plate; and interbody Systems, such as Battalion Universal Spacer System, Novel PEEK and Titanium Spinal Spacers, and Alphatec Solus Locking ALIF Spinal Spacer. In addition, the company offers biologics consisting of AlphaGraft Structural Allograft Spacers, AlphaGraft ProFuse Demineralized Bone Scaffold, Amnioshield Amniotic Tissue Barrier, Alphagraft Demineralized Bone Matrix, and Neocore Osteoconductive Matrix. It sells its products through a network of independent distributors and direct sales representatives in the United States. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

FRESENIUS SE &/S Company Profile

Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis- related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products used in the collection and processing of blood components, as well as in transfusion medicine. The Fresenius Helios segment operates 111 hospitals with approximately 35,000 beds, such as 88 acute care hospitals and 23 post-acute care clinics; 4 post-acute care centers; 17 prevention centers; and 12 nursing homes. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply